Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

96.54 -1.05 (-1.08%)
Streaming Delayed Price Updated: 2:27 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Regulatory Shadow Over Saudi Golf League LIV And PGA Tour Merger, Novo Nordisk's Weight Loss Drugs May Pose Serious Stomach Risks, Netflix's Local Content and Pricing Woes Undermine Growth in India: Today's Top Stories
Bloomberg Regulatory Shadow Over Saudi Golf League LIV And PGA Tour Merger 
Via Benzinga
Better Growth Stock: Novo Nordisk vs. Pfizer
Which of these two pharmaceutical giants should you add to your portfolio? 
Via The Motley Fool
Novo Nordisk's Weight Loss Drugs Like Wegovy, Ozempic May Pose Serious Stomach Risks, Study Suggests
A recent study published in JAMA has raised concerns about the potential risks associated with popular weight loss and diabetes drugs like Novo Nordisk A/S's (NYSE: NVO), Wegovy (semaglutide), Ozempic... 
Via Benzinga
2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not
Eli Lilly's drug looks better on paper, but Ozempic was on the market first. 
Via The Motley Fool
ConAgra's Snack Revolution - Portion Sizes May Get A Makeover Amid Diet Drug Wave: Report
ConAgra Brands, Inc. (NYSE: CAG) could reportedly revamp the portion sizes of its snacks should the rising tide of  
Via Benzinga
Why Insulet Stock Traded Lower
Insulet Corporation (NASDAQ: PODD) shares traded lower Thursday. 
Via Benzinga
Biggest Oil Drop In A Year On Biden Security Plan, Magnificent 7 Stocks Do Not Like The New Data
To gain an edge, this is what you need to know today. 
Via Benzinga
Disney Slashes Ticket Prices For Children, US Government Ceases Free Distribution Of Merck COVID Pill, UK Deep Dives Into Amazon And Microsoft's Cloud Power: Today's Top Stories
CNBC Disney Slashes Children's Ticket Prices Amid Attendance Slump 
Via Benzinga
Exposures COVID-19
Novo Nordisk's Wegovy Success Uplifts Denmark's Economy And Reputation, But With Caution
Novo Nordisk A/S's (NYSE: NVO) remarkable success with its weight-loss treatment, Wegovy, is not only a cause for celebration but also a source of  
Via Benzinga
Topics Economy
Exposures Economy
3 Dividend Stocks That Turned $25,000 into $100,000 in 10 Years -- and None of Them Is a Tech Stock
These stocks may not be done rising in value just yet. 
Via The Motley Fool
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
This stock puts the "big" in big pharma after massive gains in recent years. 
Via The Motley Fool
Walmart Reports 'Slight Pullback' In Food Demand As 'Miracle' Weight-Loss Drug Ozempic Gains Popularity
Via Benzinga
2 Magnificent Growth Stocks to Buy Right Now
These two biotech stocks could be big winners for patient investors. 
Via The Motley Fool
1 Stock-Split Stock to Buy Hand Over Fist in October and 1 to Avoid
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's one historically cheap stock-split stock, as well as another company that carries... 
Via The Motley Fool
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration  
Via Benzinga
Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost
Novo Holdings, the controlling shareholder of Novo Nordisk A/S (NYSE: NVO), is bracing for a significant influx of capital stemming from the thriving success of the weight-loss drug Wegovy.  
Via Benzinga
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Benzinga 
Via Benzinga
Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner
Novo Nordisk A/S (NYSE: NVO) successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs,  
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Meet Soleno Therapeutics, The Company Whose Hunger Suppressant Sent Shares Flying 505%
Soleno Therapeutics is working on a treatment for Prader Willi syndrome, a genetic disease that causes obesity. 
Via Investor's Business Daily
Why Shares of Structure Therapeutics Are Up Monday
The stock climbed for the second straight day after the company reported positive trial data for its weight-loss therapy drug. 
Via The Motley Fool
Big Pharma's Weight Loss Drugs Vs. Snacking Industry: Who Will Prevail?
The rising prevalence of obesity and diabetes drugs like Novo Nordisk A/S's (NYSE: NVO) Wegovy and Ozempic is triggering concerns among investors about the future of the snacking industry.  
Via Benzinga
Stable Giants: 3 Bigwig Biotech Stocks for Consistent Returns
These biotech stocks, Thermo Fisher, Novo Nordisk, and Eli Lilly, will bring consistent returns in the volatile biotech sector. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 2, 2023
Via Benzinga
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
Via AB Newswire
Topics Death
Exposures Death Product Safety
What A Government Shutdown Could Mean For You
In a nail-biting development amid fears of a government shutdown, the House has passed a bipartisan bill, narrowly averting the blackout as the midnight deadline looms. 
Via Benzinga
These 5 Stocks Are Setting Up This Buying Opportunity After Strong Runs
Stocks can offer a new buying opportunity with a pullback to the 50-day line. 
Via Investor's Business Daily
Why Shares of Structure Therapeutics Are Soaring on Friday
The company reported positive results from an early-stage clinical trial for its weight-loss therapy candidate. 
Via The Motley Fool
Newcomer Structure Throws Down The Gauntlet In Obesity Treatment -- Shares Soar 66%
The company is working on a pill to help weight loss, rivaling shots from Novo and, possibly, Lilly. 
Via Investor's Business Daily
Why Is Obesity Focused Structure Therapeutics Stock Trading Higher Today?
Structure Therapeutics Inc (NASDAQ: GPCR) released results from the Phase 1b multiple ascending dose (MAD) study of GSBR-1290 in healthy, overweight, or  
Via Benzinga
Novo Nordisk Targets High Demand Indian Market For Its Popular Obesity Drugs Like Wegovy
Danish pharma giant Novo Nordisk A/s (NYSE: NVO) has set its sights on India for the introduction of its breakthrough  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.